Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Friday morning. The firm issued a hold rating on the stock.

A number of other brokerages have also commented on EKSO. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a report on Tuesday, March 4th. Lake Street Capital dropped their price target on shares of Ekso Bionics from $2.00 to $1.00 and set a “buy” rating on the stock in a research report on Tuesday, March 4th.

Ekso Bionics Trading Down 9.7 %

Ekso Bionics stock opened at $0.38 on Friday. Ekso Bionics has a 52-week low of $0.34 and a 52-week high of $1.53. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $9.38 million, a price-to-earnings ratio of -0.58 and a beta of 1.33. The firm has a 50-day moving average price of $0.50 and a two-hundred day moving average price of $0.71.

Ekso Bionics (NASDAQ:EKSO) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.07). Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. The business had revenue of $5.09 million for the quarter, compared to analyst estimates of $5.05 million. Sell-side analysts expect that Ekso Bionics will post -0.48 earnings per share for the current year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.